









Markets
/
Stocks
/
nasdaq-asnd
/

Ascendis Pharma A/S

ASND

224.460USD

+0.510+0.23%

Market hours （ET）Quotes delayed by 15 min

13.85BMarket Cap

LossP/E TTM



Ascendis Pharma A/S

224.460

+0.510+0.23%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ascendis Pharma A/S

Currency: USD Updated: 2026-01-29

Key Insights

Ascendis Pharma A/S's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 2 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 267.48.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ascendis Pharma A/S's Score

Industry at a Glance

Industry Ranking

2 / 393

Overall Ranking

29 / 4540

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ascendis Pharma A/S Highlights

StrengthsRisks

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 719.04% year-on-year.

Undervalued

The company’s latest PE is -22.07, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 68.62M shares, increasing 0.00% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 690.00 shares of this stock.

Analyst Rating

Based on 17 analysts

Strong Buy

Current Rating

267.478

Target Price

+12.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-29

The current financial score of Ascendis Pharma A/S is 8.26, ranking 51 out of 393 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 184.29M, representing a year-over-year increase of 235.56%, while its net profit experienced a year-over-year increase of 44.15%.

Score

Industry at a Glance

Previous score

8.26

Change



Financials

6.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.02

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Ascendis Pharma A/S's Company Valuation

Currency: USD Updated: 2026-01-29

The current valuation score of Ascendis Pharma A/S is 7.24, ranking 146 out of 393 in the Biotechnology & Medical Research industry. Its current P/E ratio is -22.07, which is -66.20% below the recent high of -7.46 and -6.63% above the recent low of -23.53.

Score

Industry at a Glance

Previous score

7.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 2/393

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-29

The current earnings forecast score of Ascendis Pharma A/S is 9.06, ranking 15 out of 393 in the Biotechnology & Medical Research industry. The average price target is 254.00, with a high of 325.00 and a low of 220.00.

Score

Industry at a Glance

Previous score

9.06

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 17 analysts

Strong Buy

Current Rating

267.478

Target Price

+12.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

541

Total

Median

Average

Company name

Ratings

Analysts

Ascendis Pharma A/S

ASND

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

108

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-29

The current price momentum score of Ascendis Pharma A/S is 9.18, ranking 41 out of 393 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 247.94 and the support level at 194.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.10

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

2.364

Buy

RSI(14)

54.536

Neutral

STOCH(KDJ)(9,3,3)

64.420

Sell

ATR(14)

12.380

Low Volatility

CCI(14)

31.312

Neutral

Williams %R

33.476

Buy

TRIX(12,20)

0.380

Sell

StochRSI(14)

6.650

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

230.848

Sell

MA10

223.600

Buy

MA20

217.556

Buy

MA50

212.138

Buy

MA100

207.000

Buy

MA200

190.429

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-29

The current institutional shareholding score of Ascendis Pharma A/S is 10.00, ranking 1 out of 393 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 116.45%, representing a quarter-over-quarter increase of 3.61%. The largest institutional shareholder is PRFDX, holding a total of 1.73M shares, representing 2.79% of shares outstanding, with 25.46% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

10.28M

Westfield Capital Management Company, L.P.

5.26M

-3.51%

Avoro Capital Advisors LLC

5.11M

+2.61%

Janus Henderson Investors

4.32M

-2.37%

Fidelity Management & Research Company LLC

4.12M

-1.42%

Artisan Partners Limited Partnership

3.72M

-6.75%

Capital International Investors

3.06M

+0.45%

T. Rowe Price Investment Management, Inc.

2.67M

-25.59%

MFS Investment Management

1.88M

-1.00%

Wellington Management Company, LLP

1.80M

+95.94%

Risk Assessment

Currency: USD Updated: 2026-01-29

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ascendis Pharma A/S is 7.61, ranking 10 out of 393 in the Biotechnology & Medical Research industry. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.